Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Home Page: www.abbvie.com
1 North Waukegan Road
North Chicago,
IL
60064-6400
United States
Phone:
847 932 7900
Officers
| Name | Title |
|---|---|
| Mr. Richard A. Gonzalez | Executive Chairman |
| Mr. Robert A. Michael | CEO & Director |
| Mr. Scott T. Reents | Executive VP & CFO |
| Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer |
| Dr. Roopal Thakkar M.D. | Executive VP of Research and Development & Chief Scientific Officer |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary |
| Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal |
| Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer |
Exchange: XETRA
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 14.7493 |
|---|---|
| Trailing PE: | 61.0184 |
| Price-to-Book MRQ: | 51.2795 |
| Price-to-Sales TTM: | 5.3329 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 50000 |